DAPAYES
DAPAYES
Dapagliflozin 10 mg Tablet
To improve glycemic control
In T2D with multiple risk factors,
Selecvely inhibits SGLT2 in the renal proximal tubule
Lowers glycemia independently of β-cell funcon and
1–4 insulin resistance
Induces urinary glucose excreon, resulng in a reducon
of blood glucose
Beyond HbA1c – It offers
Blood pressure reducon
Weight reducon
Risks/Limitaons : eGFR > 45-60 ml/min
Reduced the risk of CV death or heart failure hospitalizaon
